Phase I Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of OBI-858 for Treatment of Glabellar Lines
Abstract Introduction OBI-858 is a brand-new botulinum Type A complex toxin with a specific molecular weight of 760 kDa intended for development for both aesthetic and therapeutic applications. This is a phase I, dose-escalation study to evaluate the safety and preliminary efficacy of OBI-858 in sub...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Adis, Springer Healthcare
2024-11-01
|
| Schriftenreihe: | Dermatology and Therapy |
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.1007/s13555-024-01309-7 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|